Page 25 - MEMOCiberes014-ENG

COPD Cohort will be generated in the CIBERES Strategic Project on COPD . The objective of this work is to clinically and molecularly characterize patients with LC in this Cohort, to establish links between LC and COPD, and to verify molecular variables that differentiate cases identified by screening from cases diagnosed in clinical practice .
Aims and objectives
1. To identify a set of clinico-molecular variables that improve the prognostic and predictive capacity of the TNM staging in LC.
Analysis of biological and molecular variables that have prognostic and/or predictive value with respect the therapeutic response, independently of TNM staging, in tumour samples, pulmonary tissue, lymph nodes and peripheral blood will include:
• Epigenetics, according to the methylation pattern of chosen genes
• Immunohistochemistry, determining alterations of the stroma.
• Analysis of inflammation and oxidative stress, by measuring biomarker levels in tumour tissue and blood
2. To validate in a population of smokers with COPD screening techniques developed for the general population, and to validate in the former population prognostic and predictive clinic-molecular variables.
The specific aims for this population are:
• To create a high-performance cost-effective screening methodology for stage I/IIp LC.
• To identify biological and molecular variables with potential prognostic and/or predictive va- lue independently of the pathological TNM, in samples of tumour tissue, non-tumour lung tissue, lymph nodes and peripheral blood from patients with squamous/adenocarcinoma- type NSCLC, identified by a screening programme .
• To identify biological variables associated with the early diagnosis of NSCLC by screening (Early-COPD Cohort), compared with the usual care clinical diagnosis (GCCP-II-IASLC and CIBERES Cohorts) .
• To study the potential correlation between the activity of molecular variables for COPD and LC .
Main results until the end of 2014
• Confirmation of the prognostic usefulness of the epigenetic analysis of tumour cells obtained by semi-invasive techniques and processes as a cell block .
• Definition of markers related to patient mortality in stages II and III, identified with this type of cytological approach .
• The Programme has successfully created a tumour tissue biobank containing tumour tissues from patients included in the International Association for the Study of Lung Cancer (IASLC) Cohort and in follow-up until 2016 . It has over 250 samples available for the analysis of biological markers with potential prognostic capacity . Baseline clinical information of the patients included in this Cohort living in this territory was published by CIBERES researchers participating in the Programme (Sanchez of Cos J . Arch Bronconeumol [Barc] 2013) in 2013 .
In the technological Innovations Line the Cancer CRP can show the following results:
• GUIBRO Project . Seventy-five (75) patients recruited with SPN, studied with ultra-fine bronchoscopy and radial EBUS . The preliminary results were presented in a correlative manner in conferences
www.ciberes.org 25